{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T18:19:51Z","timestamp":1758478791852,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,3,16]]},"DOI":"10.1038\/s41416-020-01214-8","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T07:03:03Z","timestamp":1608274983000},"page":"1177-1178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comment on \u201cHeterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy\u201d"],"prefix":"10.1038","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-5910","authenticated-orcid":false,"given":"Haitang","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean R. R.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9635-9581","authenticated-orcid":false,"given":"Feng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"1214_CR1","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/modpathol.2016.188","volume":"30","author":"NM Joseph","year":"2017","unstructured":"Joseph, N. M., Chen, Y. Y., Nasr, A., Yeh, I., Talevich, E., Onodera, C. et al. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X. Mod. Pathol. 30, 246\u2013254 (2017).","journal-title":"Mod. Pathol."},{"key":"1214_CR2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., De Rienzo, A., Modrusan, Z. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407\u2013416 (2016).","journal-title":"Nat. Genet."},{"key":"1214_CR3","doi-asserted-by":"publisher","unstructured":"White, M. G., Schulte, J. J., Xue, L., Berger, Y., Schuitevoerder, D., Vining, C. C. et al. Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. Br. J. Cancer https:\/\/doi.org\/10.1038\/s41416-020-01130-x (2020).","DOI":"10.1038\/s41416-020-01130-x"},{"key":"1214_CR4","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","volume":"31","author":"S Popat","year":"2019","unstructured":"Popat, S., Curioni-Fontecedro, A., Polydoropoulou, V., Shah, R., O\u2019Brien, M., Pope, A. et al. A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann. Oncol. 31, 1734\u20131745 (2019).","journal-title":"Ann. Oncol."},{"key":"1214_CR5","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1158\/1078-0432.CCR-20-1767","volume":"26","author":"R Chen","year":"2020","unstructured":"Chen, R., Lee, W. C., Fujimoto, J., Li, J., Hu, X., Mehran, R. et al. Evolution of genomic and T cell repertoire heterogeneity of malignant pleural mesothelioma under dasatinib treatment. Clin. Cancer Res. 26, 5477\u20135486 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1214_CR6","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.3390\/cancers12082310","volume":"12","author":"H Yang","year":"2020","unstructured":"Yang, H., Xu, D., Yang, Z., Yao, F., Zhao, H., Schmid, R. A. et al. Systematic analysis of aberrant biochemical networks and potential drug vulnerabilities induced by tumor suppressor loss in malignant pleural mesothelioma. Cancers 12, 2310 (2020).","journal-title":"Cancers"},{"key":"1214_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09307-6","volume":"10","author":"Y Blum","year":"2019","unstructured":"Blum, Y., Meiller, C., Quetel, L., Elarouci, N., Ayadi, M., Tashtanbaeva, D. et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat. Commun. 10, 1333 (2019).","journal-title":"Nat. Commun."},{"key":"1214_CR8","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.chest.2020.06.077","volume":"158","author":"H Yang","year":"2020","unstructured":"Yang, H., Hall, S. R. R. & Yao, F. The value of PD-L1 expression in metastatic lymph nodes of advanced non-small cell lung cancer. Chest 158, 1785\u20131787 (2020).","journal-title":"Chest"},{"key":"1214_CR9","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.chest.2020.04.059","volume":"158","author":"F Perrotta","year":"2020","unstructured":"Perrotta, F., Nankivell, M., Adizie, J. B., Maqsood, U., Elshafi, M., Jafri, S. et al. Endobronchial ultrasound-guided transbronchial needle aspiration for PD-L1 testing in non-small cell lung cancer. Chest 158, 1230\u20131239 (2020).","journal-title":"Chest"},{"key":"1214_CR10","doi-asserted-by":"publisher","unstructured":"Zhou, K. I., Peterson, B. F., Serritella, A., Thomas, J., Reizine, N., Moya, S. et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2085 (2020).","DOI":"10.1158\/1078-0432.CCR-20-2085"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01214-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01214-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01214-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T01:02:14Z","timestamp":1639789334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01214-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,3,16]]}},"alternative-id":["1214"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-01214-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2020,12,18]]},"assertion":[{"value":"28 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All informed consents were obtained. This report does not contain any individual person\u2019s information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}